|Bid||93.36 x 800|
|Ask||94.07 x 3200|
|Day's Range||93.32 - 94.69|
|52 Week Range||58.59 - 95.44|
|Beta (3Y Monthly)||2.03|
|PE Ratio (TTM)||17.02|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Bristol-Myers Squibb Company announced today the commencement, in connection with its previously announced acquisition of Celgene Corporation , of an exchange offer for any and all outstanding notes issued by Celgene for up to $19,850,000,000 aggregate principal amount of new notes to be issued by Bristol-Myers Squibb and cash.
Celgene Corporation (CELG) today announced that its stockholders have voted to approve the company’s proposed combination with Bristol-Myers Squibb Company (BMY). Approximately 98% of the votes cast, and over 70% of the shares outstanding and entitled to vote, voted in favor of the transaction at the special meeting. “On behalf of the Celgene Board of Directors, I would like to thank our stockholders for their overwhelming support of this transaction,” said Mark Alles, Chairman and Chief Executive Officer of Celgene.
Celgene Corporation (CELG) and Acceleron Pharma Inc. (XLRN) today announced that Celgene has submitted a Biologics License Application (BLA) for luspatercept, an erythroid maturation agent, for the treatment of adult patients with very low to intermediate risk myelodysplastic syndromes (MDS)-associated anemia who have ring sideroblasts and require red blood cell (RBC) transfusions and for the treatment of adult patients with beta-thalassemia-associated anemia who require RBC transfusions.
The CHMP adopted two positive opinions recommending European Commission approval of:
Celgene Corporation (CELG) today announced that the Company has submitted a New Drug Application to the U.S. Food and Drug Administration (FDA) for ozanimod for the treatment of adults with relapsing forms of multiple sclerosis (RMS). Ozanimod is an oral, sphingosine 1-phosphate (S1P) receptor modulator, which binds with high affinity selectively to S1P subtypes 1 (S1P1) and 5 (S1P5). The pivotal efficacy and safety data provided in the application result from the SUNBEAM™ and RADIANCE™ Part B phase 3, multicenter, randomized, double-blind, double-dummy, active-controlled trials.
Bristol-Myers Squibb Company’s (BMY) Board of Directors today sent an open letter to the Company’s shareholders regarding the previously announced definitive merger agreement with Celgene Corporation (CELG). In addition to its March 19 investor presentation, the Company today also made available on Bristol-Myers Squibb’s website at www.bestofbiopharma.com and later today will file with the Securities and Exchange Commission (SEC) an investor presentation providing an overview of Bristol-Myers Squibb’s ability to derive value from Celgene’s pipeline and a Fact Sheet providing additional detail on key benefits of the transaction.
TECENTRIQ® in Combination with ABRAXANE® receives accelerated approval for people with PD-L1-Positive, Metastatic Triple-Negative Breast Cancer
Celgene Corporation (CELG) today announced that the Company has submitted a Marketing Authorization Application to the European Medicines Agency (EMA) for ozanimod for the treatment of adults with relapsing-remitting multiple sclerosis (RRMS). Ozanimod is an oral, sphingosine 1-phosphate (S1P) receptor modulator, which binds with high affinity selectively to S1P subtypes 1 (S1P1) and 5 (S1P5). The pivotal efficacy and safety data provided in the application result from the SUNBEAM™ and RADIANCE™ Part B phase 3, multicenter, randomized, double-blind, double-dummy, active-controlled trials.
Celgene Corporation (CELG) today announced the U.S. Food and Drug Administration (FDA) has accepted the company’s New Drug Application (NDA) for fedratinib and granted a Priority Review. Fedratinib is a highly selective JAK2 inhibitor intended for the treatment of patients with myelofibrosis, a serious bone marrow disorder that disrupts the body’s normal production of blood cells.1 Under the Prescription Drug User Fee Act, the FDA has set its action date as Sept. 3, 2019.
NEW YORK, Feb. 27, 2019 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
U.S. FDA grants Priority Review for REVLIMID® in combination with rituximab for previously treated follicular and marginal zone lymphoma
The Complaint alleges that on January 2, 2019, Celgene, Bristol-Myers Squibb Company (“BMS” or “Parent”), and Burgundy Merger Sub, Inc., a direct wholly-owned Subsidiary of Parent (“BM Merger Sub”), entered into an Agreement and Plan of Merger (the “Merger Agreement”). Pursuant to the Merger Agreement BM Merger Sub will merge with and into Celgene, with Celgene surviving the merger and becoming a wholly-owned Subsidiary of Parent (the “Proposed Transaction”).
NEW YORK , Feb. 14, 2019 /PRNewswire/ -- Celgene Corporation (CELG) Lifshitz & Miller announces investigation into possible breaches of fiduciary duties in connection with the proposed merger of Celgene ...
Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC are investigating the proposed sale of Celgene Corporation to Bristol-Myers Squibb Company .
NEW YORK, Feb. 5, 2019 /PRNewswire/ -- Lyfebulb, a chronic disease-focused, patient-empowerment platform that connects patients with industry and investors to support user-driven innovation, and Celgene Corporation (CELG) announced the Lyfebulb-Celgene 2019 "Addressing Unmet Needs in MS: An Innovation Challenge" is now accepting applications. The goal of the initiative is to seek new solutions, beyond therapy, to help address either challenges faced by people with multiple sclerosis (MS) in their daily lives or an unmet need that could potentially improve outcomes and experiences for both people with the disease and their support partners. The Innovation Challenge will take place in June 2019 and will be open to patient entrepreneurs—those who have been affected by MS as either a patient, loved one or support partner—whose companies are helping develop solutions to address an unmet need in MS.
NEW YORK, NY / ACCESSWIRE / January 29, 2019 / U.S. equities plunged on Monday following Caterpillar’s weaker-than-expected earnings report that dragged the tech sector lower. Additionally, fears over ...
Celgene’s stock moved 0.58% higher Wednesday, to close the day at $86.50. The stock recorded a trading volume of 9,036,001 shares, which was below its three months average volume of 9,822,850 shares. In the last year, Celgene’s shares have traded in a range of 58.59 - 106.67.
NEW YORK , Jan. 13, 2019 /PRNewswire/ -- Juan Monteverde , founder and managing partner at Monteverde & Associates PC , a national securities firm headquartered at the Empire State Building in New York ...
HENDERSON, NV / ACCESSWIRE / January 9, 2019 / With huge deals biotech and cannabinoid-based companies have been reporting lately, the space looks poised for a big 2019. One we like is cannabinoid-based ...
NEW ORLEANS , Jan. 8, 2019 /PRNewswire/ -- Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC ("KSF") are investigating the proposed sale ...
HENDERSON, NV / ACCESSWIRE / January 8, 2019 / Bristol-Myers Squibb announced a deal Thursday, buying Celgene Corp. for $74 billion. Investors in other growing cancer treatment companies should pay attention, ...
SUMMIT, N.J.-- -- Company achieved its latest full-year 2018 guidance; will report Q4 2018 results on January 31, 2019 Provides full-year 2019 guidance and reaffirms 2020 outlook Fedratinib NDA and REVLIMID ® sNDA submitted; ozanimod regulatory submissions on-track for Q1 2019 Celgene Corporation today provides a business update, including confirmation that the company achieved its guidance for full-year ...
Do you own shares of Celgene Corporation (NASDAQ GS: CELG)? Rigrodsky & Long, P.A. announces that it is investigating potential legal claims against the board of directors of Celgene Corporation (“Celgene” or the “Company”) (NASDAQ GS: CELG) regarding possible breaches of fiduciary duties and other violations of law related to the Company’s entry into an agreement to merge with Bristol-Myers Squibb Company (“Bristol-Myers”) (NYSE: BMY) in a transaction valued at approximately $74 billion. Under the terms of the agreement, shareholders of Celgene will receive 1.0 Bristol-Myers Squibb share and $50.00 in cash for each share of Celgene common stock.
NEW YORK, Jan. 04, 2019 -- The following statement is being issued by Levi & Korsinsky, LLP: To: All Persons or Entities who purchased Celgene Corporation (“Celgene” or.